Kolexia
Vegas Helene Oncologie médicale
Vegas Helene
Oncologie médicale
Centre hospitalier de Tours
Tours, France
62 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du sein Sarcomes Neutropénie Lymphopénie Chondrosarcome Tumeurs osseuses Sarcome du stroma endométrial Tumeurs de l'ovaire Carcinome épithélial de l'ovaire

Collaborateurs

Voir plus
Linassier Claude
Linassier Claude
Centre hospitalier de Tours, Tours, France
By Marie-Agnes
By Marie-Agnes
Centre hospitalier de Tours, Tours, France
Stacoffe Marion
Stacoffe Marion
Centre Hospitalier de Chinon, Chinon, France
Narciso Berengere
Narciso Berengere
Centre hospitalier de Tours, Tours, France

Industries

Voir plus
Novartis
9 collaboration(s)
Dernière en 2022
AstraZeneca
9 collaboration(s)
Dernière en 2023
Eisai
5 collaboration(s)
Dernière en 2022
Pfizer
5 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
REPARP: Prospective and Multicentric Study Evaluating DNA Double-strand Breaks (DSBs) REpair Factors (POLQ, Shieldin Complex and 53BP1) Expression as Biomarker of PARP Inhibitor Resistance in Patients With Deleterious Germline Mutation in BRCA 1/2 and HER2-negative, Metastatic or Locally Advanced Breast Cancer.
Essai Clinique (Artios Pharma Ltd)   26 février 2024
REGOBONE: A Randomized Phase II, Placebo-controlled, Multicenter Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas
Essai Clinique (Unicancer)   06 novembre 2023
InTTercePT: Treatment With Tucatinib in Addition to Pertuzumab and Trastuzumab in Patients With HER2-positive Metastatic Breast Cancer After Local Therapy of Isolated Brain Progression
Essai Clinique (Seagen)   21 septembre 2023
PADA-1: Randomized, Open Label, Multicentric Phase III Trial to Evaluate the Safety and Efficacy of Palbociclib in Combination With HT Driven by ctDNA ESR1 Mutation Monitoring in ER+, HER2-negative Metastatic Breast Cancer Patients
Essai Clinique (Pfizer)   21 septembre 2023
TAPAZ: A Randomized Phase II Study of Pazopanib and Weekly Paclitaxel in Patients With Platinum Resistant/Refractory Ovarian Cancer Who Relapse During Bevacizumab Maintenance
Essai Clinique (Novartis)   05 septembre 2023
BFR-ESS: Randomized Comparative Prospective Multicentre Phase II Trial Evaluating Clinical Impact of Interruption VS Maintenance of AI in Patients With Locally Advanced/ Metastatic LGESS
Essai Clinique (Centre Léon-Bérard)   31 août 2023
Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial.
The Lancet. Oncology   29 septembre 2022
Paclitaxel with or without pazopanib for ovarian cancer relapsing during bevacizumab maintenance therapy: The GINECO randomized phase II TAPAZ study.
Gynecologic oncology   26 juillet 2022
Unexpected severe hepatic and skin toxicities during high dose methotrexate course for osteosarcoma.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners   09 février 2022
822TiP BFR ESS: A randomized phase II trial from the GSF/GETO French group evaluating the impact of interruption versus maintenance of aromatase inhibitors in patients with advanced or metastatic low grade endometrial stromal sarcoma after at least 3 years of therapy
Abstract Book of the ESMO Congress 2021, 16 – 21 September 2021   01 septembre 2021